Phase III success for first-in-class pulmonary hypertension drug

Abstract

Data presented at the recent annual conference of the American College of Chest Physicians (ACCP) by Bayer for its oral soluble guanylyl cyclase (sGC) stimulator riociguat generated high hopes for the drug's potential in the treatment of pulmonary hypertension (PH). The primary end points were met in both of the pivotal Phase III studies, in which riociguat was evaluated in patients with pulmonary arterial hypertension (PAH) or in patients with inoperable or residual chronic thromboembolic pulmonary hypertension (CTEPH).